Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056299 · ClinicalTrials.gov registry record · Phase 2
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
A Phase 2 study, sponsored by Aimmune Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04056299: Clinical Trial Phase 2 study, sponsored by Aimmune Therapeutics.
NCT04056299 is a Phase 2 study that was terminated before completion, run by Aimmune Therapeutics. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04056299, a Phase 2 study, was terminated before completion, sponsored by Aimmune Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
To determine the efficacy and safety of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
Interventions
- BIOLOGICAL AR201 powder
- BIOLOGICAL Placebo powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-08-20 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
Why NCT04056299 stopped before completion
NCT04056299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which AR201 powder is the first listed.
NCT04056299 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04056299 about?
NCT04056299 is a clinical study titled "Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy". To determine the efficacy and safety of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
What is the current status of trial NCT04056299?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-08-20. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT04056299?
The interventions under investigation include: AR201 powder (BIOLOGICAL), Placebo powder (BIOLOGICAL).
Who is sponsoring clinical trial NCT04056299?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04056299's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI